Chua Terence C, Morris David L
UNSW Department of Surgery, Hepatobiliary and Surgical Oncology Unit, St George Hospital, Sydney, Australia.
Scand J Gastroenterol. 2012 Mar;47(3):258-68. doi: 10.3109/00365521.2012.640823. Epub 2011 Dec 19.
Evidence of the clinical benefit of surgery or metastasectomy for metastatic colorectal cancer to disease sites including the liver, lung, peritoneum, and pelvis as a potentially curative option is now available in the literature. The oncologic outcome of this treatment strategy achieves 5-year survival ranging between 20% and 50%. These survival gains have not been previously observed in the management of metastatic colorectal cancer. Treatment of potential surgical candidates requires a combined modality approach with systemic therapies to achieve macroscopic tumor removal and microscopic targeting of tumor deposits to achieve disease control. In nonsurgical candidates, systemic therapy, radiation therapy, and interventional oncology procedures may potentially facilitate sufficient disease downstaging for surgery. The purpose of this article is to provide a comprehensive review of the therapeutic advances in the surgical management of metastatic colorectal cancer.
手术或转移灶切除术对包括肝脏、肺、腹膜和骨盆等疾病部位的转移性结直肠癌作为一种潜在的治愈性选择的临床益处的证据目前在文献中已有报道。这种治疗策略的肿瘤学结果实现了20%至50%的5年生存率。这些生存获益在转移性结直肠癌的治疗中此前尚未观察到。对潜在手术候选者的治疗需要采用全身治疗的联合模式方法,以实现宏观肿瘤切除和肿瘤沉积物的微观靶向,从而实现疾病控制。对于非手术候选者,全身治疗、放射治疗和介入肿瘤学程序可能有助于实现足够的疾病降期以便进行手术。本文的目的是对转移性结直肠癌手术治疗的治疗进展进行全面综述。